Australia markets open in 52 minutes

Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.7300-0.0500 (-1.80%)
At close: 04:00PM EDT
2.7400 +0.01 (+0.37%)
After hours: 06:59PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
18,141
18,141
39,019
10,988
6,914
Cost of revenue
-
-
-
-
47,481
Gross profit
-
-
-
-
-40,567
Operating expenses
Research development
73,700
73,700
84,408
65,502
49,338
Selling general and administrative
22,475
22,475
17,834
17,136
14,845
Total operating expenses
96,175
96,175
102,242
82,638
64,183
Operating income or loss
-78,034
-78,034
-63,223
-71,650
-57,269
Interest expense
459
459
1,726
2,857
4,011
Total other income/expenses net
-44
-44
-2,255
-1,867
-3,206
Income before tax
-72,849
-72,849
-65,012
-76,247
-63,745
Income tax expense
0
0
4,444
0
0
Income from continuing operations
-72,849
-72,849
-69,456
-76,247
-63,745
Net income
-72,849
-72,849
-69,456
-76,247
-63,745
Net income available to common shareholders
-72,849
-72,849
-69,456
-88,386
-75,868
Basic EPS
-0.46
-
-0.46
-0.83
-1.00
Diluted EPS
-0.46
-
-0.46
-0.83
-1.00
Basic average shares
162,714
-
150,939
106,242
75,835
Diluted average shares
162,714
-
150,939
106,242
75,835